Toxicity and feasibility of vincristine, etoposide, and carboplatin alternating with vincristine, doxorubicin, and cyclophosphamide in children with advanced retinoblastoma in Guatemala.
Toxicity and feasibility of vincristine, etoposide, and carboplatin alternating with vincristine, doxorubicin, and cyclophosphamide in children with advanced retinoblastoma in Guatemala.
复制标题
长春新碱、依托泊苷和卡铂与长春新碱、阿霉素和环磷酰胺交替使用对危地马拉晚期视网膜母细胞瘤儿童的毒性和可行性。
DOI：
10.1002/pbc.30392
复制
发表时间：
2023
影响因子：
3.2
通讯作者：
Luna-Fineman,Sandra
中科院分区：
文献类型：
--
作者：
Graff,Zachary;Giron,Veronica;Miller,Kristen;Pixtun,Dyna;Alejos,Amanda;Luna-Fineman,Sandra
Retinoblastoma is highly curable, with event‐free survival (EFS) of greater than 95% in high‐income countries. However, in lower middle‐income countries, outcomes of EFS are 30%–60% due to delayed diagnosis and lack of resources resulting in extra‐ocular disease. We report the toxicity profile and outcomes of intensified therapy for advanced retinoblastoma: vincristine, etoposide, carboplatin (VEC) alternating with vincristine, doxorubicin, and cyclophosphamide (VDoCx) in Guatemala. Compared to VEC alone, similar rates of neutropenia, anemia, and thrombocytopenia were seen, with no toxic deaths. Although survival was not a primary objective, a modest survival benefit supports further investigation of VEC+VDoCx for advanced retinoblastoma.
